Rosell Axel, Havervall Sebastian, von Meijenfeldt Fien, Hisada Yohei, Aguilera Katherina, Grover Steven P, Lisman Ton, Mackman Nigel, Thålin Charlotte
Division of Internal Medicine, Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden (A.R., S.H., K.A., C.T.).
Surgical Research Laboratory, Department of Surgery, University of Groningen, University Medical Center Groningen, the Netherlands (F.v.M., T.L.).
Arterioscler Thromb Vasc Biol. 2021 Feb;41(2):878-882. doi: 10.1161/ATVBAHA.120.315547. Epub 2020 Dec 3.
Patients with coronavirus disease 2019 (COVID-19) have a high rate of thrombosis. We hypothesized that severe acute respiratory syndrome coronavirus 2 infection leads to induction of TF (tissue factor) expression and increased levels of circulating TF-positive extracellular vesicles (EV) that may drive thrombosis. Approach and Results: We measured levels of plasma EV TF activity in 100 patients with COVID-19 with moderate and severe disease and 28 healthy controls. Levels of EV TF activity were significantly higher in patients with COVID-19 compared with controls. In addition, levels of EV TF activity were associated with disease severity and mortality. Finally, levels of EV TF activity correlated with several plasma markers, including D-dimer, which has been shown to be associated with thrombosis in patients with COVID-19.
Our results indicate that severe acute respiratory syndrome coronavirus 2 infection induces the release of TF-positive EVs into the circulation that are likely to contribute to thrombosis in patients with COVID-19. EV TF activity was also associated with severity and mortality.
2019冠状病毒病(COVID-19)患者的血栓形成率很高。我们推测,严重急性呼吸综合征冠状病毒2感染会导致组织因子(TF)表达的诱导以及循环中TF阳性细胞外囊泡(EV)水平的升高,这可能会引发血栓形成。方法与结果:我们测量了100例中重度COVID-19患者和28名健康对照者的血浆EV TF活性水平。与对照组相比,COVID-19患者的EV TF活性水平显著更高。此外,EV TF活性水平与疾病严重程度和死亡率相关。最后,EV TF活性水平与几种血浆标志物相关,包括D-二聚体,D-二聚体已被证明与COVID-19患者的血栓形成有关。
我们的结果表明,严重急性呼吸综合征冠状病毒2感染会诱导TF阳性EV释放到循环中,这可能导致COVID-19患者发生血栓形成。EV TF活性也与疾病严重程度和死亡率相关。